|05th December,2018||11:00-12:30||Track 3|
Investment in immunotherapies in 2018 is still attractive and sought for, what is its growth potential after several years of being an investment blockbuster? What have been the 2018 investment successes in immunotherapy? Will immunotherapy disrupt the oncology market? Are we at growth, maturity or saturation stage when talking about investment in immunotherapy?
Juan Garcia - BioSeed Capital
Bram VANPARYS - MS Ventures